Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTTW9V)

Drug Name

NBI-921352 Drug Info

Synonyms

Zandatrigine; XEN901; NBI-921352; XEN-901; SV2WPA4R4J; UNII-SV2WPA4R4J; 2154406-04-7; Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3S)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-N-4-thiazolyl-; Benzenesulfonamide, 2-fluoro-5-methyl-4-[methyl[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]-N-4-thiazolyl-; zandatrigine [INN]; CHEMBL4650313; SCHEMBL19613237; GTPL11734; BDBM470680; (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide formate; NBI921352; US10815229, Example 101; AKOS040757364; MS-28458; HY-147423; CS-0564178; F84519; 4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide; 4-{[(3S)-1-benzylpyrrolidin-3-yl](methyl)amino}-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Epileptic encephalopathy	8A62	Phase 2	[1]

Cross-matching ID

PubChem CID: 132141687
TTD Drug ID: DMTTW9V

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.6 (SCN8A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN901	DMRP9YF	Epilepsy	8A60-8A68	Phase 1	[3]
PRAX-330	DMHIS3M	Epilepsy	8A60-8A68	Phase 1	[4]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[5]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[5]
4,9-anhydro-tetrodotoxin	DMEKI1B	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.6 (SCN8A)	TT54ERL	SCN8A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05226780) A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Neurocrine Biosciences
3	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 583).
6	The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel. Am J Physiol Cell Physiol. 2007 Aug;293(2):C783-9.